NCT06692062 Hypofractionated Radiotherapy for Thymic Epithelial Tumors
| NCT ID | NCT06692062 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rongrong Zhou |
| Condition | Thymoma and Thymic Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2027-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2024-10-01 with a primary completion date of 2027-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if hypofractionated radiotherapy works to shorten the treatment time without increasing the side effects in patients of thymic epithelial tumors. The main questions it aims to answer are: * Does Hypofractionated radiotherapy provide better results? * Can hypofractionated radiotherapy reduce toxic and side effects compared with conventional radiotherapy? Researchers will compare the efficacy and safety of hypofractionated radiotherapy after thymic tumor surgery. Participants will: * Receive hypofractionated radiotherapy or conventional radiotherapy * Visit the hospital regularly once every 12 weeks for checkups and tests
Eligibility Criteria
Inclusion Criteria: 1. Patients must provide written informed consent. 2. 18 years old ≤ age \<75 years old. 3. Thymoma confirmed by pathology: type A, type AB, type B1, type B2, type B3. Thymic carcinoma. Patients with previous thymectomy were required to have complete surgical related data. 4. Masaoka⁃Koga ⁃ stage Ⅰ-Ⅲ 5. ECOG performance status 0-2. 6. Expected survival time \> 1 year. 7. Participants of childbearing age must agree to use effective contraception during the trial; In women of childbearing age, a serum or urine pregnancy test must be negative. 8. Patients who are not lactating. 9. Sufficient bone marrow reserve and good function of important organs. Exclusion Criteria: 1. patients with prior thoracic radiotherapy; 2. diseases not suitable for radiotherapy, such as recent myocardial infarction, active congestive heart failure; 3. Uncontrolled infectious disease or other serious medical or mental illness that may interfere with care 4. Patients with other malignant tumors that are not under stable control; 5. Known history of mental illness, substance abuse, alcohol or drug abuse. 6. Other conditions deemed unsuitable for enrollment by the attending physician.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06692062 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Thymoma and Thymic Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06692062 currently recruiting?
Yes, NCT06692062 is actively recruiting participants. Contact the research team at zhourr@csu.edu.cn for enrollment information.
Where is the NCT06692062 trial being conducted?
This trial is being conducted at Changsha, China.
Who is sponsoring the NCT06692062 clinical trial?
NCT06692062 is sponsored by Rongrong Zhou. The trial plans to enroll 100 participants.